Core Viewpoint - Johnson & Johnson has provided a sales and profit guidance for the current year that surpasses Wall Street expectations, despite anticipating a significant financial impact from a recent drug pricing agreement with the U.S. government [1][3]. Group 1: Financial Guidance - The company expects current-year sales to be between $100 billion and $101 billion, exceeding consensus estimates of $98.88 billion [4]. - Full-year earnings are projected to be between $11.43 and $11.63 per share, compared to expectations of $11.45 [4]. Group 2: Recent Developments - Johnson & Johnson agreed to lower drug prices for U.S. consumers in exchange for exemptions from broad tariffs, aligning with actions taken by other major pharmaceutical companies [2]. - This initiative is part of broader efforts by the U.S. government to reduce drug costs, particularly in the lead-up to the midterm elections [2]. Group 3: Financial Performance - For the fourth quarter, the company reported revenue of $24.56 billion, reflecting a year-over-year increase of 9.1% and surpassing projections of $24.15 billion [4]. - The strong performance was driven by high demand for medical technology products and a 27% increase in sales of the Darzalex blood cancer treatment [4]. Group 4: Earnings Performance - Adjusted earnings per share reached $2.46, exceeding analyst estimates of $2.04, despite a decline in sales of the psoriasis drug Stelara due to rising biosimilar competition [5].

The fourth quarter earnings season is picking up speed. After several big banks reported last week, more financials will deliver results, with reports from Charles Schwab (SCHW) and regional banks like Fifth Third (FITB) on the schedule. But the attention will likely shift to Netflix (NFLX) and Intel (INTC), headlining the earnings calendar. An optimistic consensus is forming: As of Jan. 16, 7% of S&P 500 (^GSPC) companies have reported fourth quarter results, according to FactSet data, and Wall Street ...

Core Insights - Johnson & Johnson (JNJ) reported earnings per share of $2.46, exceeding estimates of $2.43, and revenue of approximately $24.56 billion, surpassing the estimated $24.16 billion [1][5] Group 1: Financial Performance - The company's revenue increased by 9% during the fourth quarter, driven primarily by its cancer and autoimmune drug segments [2][5] - JNJ is positioned to potentially reach $100 billion in revenue next year as part of a new strategic initiative [2] - Despite a drug pricing deal with the Trump administration expected to impact profits by "hundreds of millions of dollars," JNJ remains optimistic about its 2026 sales and profit projections [2] Group 2: Financial Metrics - JNJ has a price-to-earnings (P/E) ratio of approximately 21.10, indicating the price investors are willing to pay for each dollar of earnings [3][5] - The price-to-sales ratio is about 5.71, reflecting the value placed on each dollar of sales [3][5] - The enterprise value to sales ratio stands at around 6.00, suggesting the company's total valuation relative to its sales [3] - The enterprise value to operating cash flow ratio is approximately 22.86, showing how the company's valuation compares to its cash flow from operations [4] - JNJ has an earnings yield of about 4.74%, providing a return on investment for shareholders [4] - The company's debt-to-equity ratio is approximately 0.58, indicating a moderate level of debt relative to equity [4] - A current ratio of around 1.07 suggests JNJ's ability to cover short-term liabilities with short-term assets [4]

To ensure this doesn’t happen in the future, please enable Javascript and cookies in your browser.If you have an ad-blocker enabled you may be blocked from proceeding. Please disable your ad-blocker and refresh. ...

After Tuesday's sharp sell-off, triggered by renewed fears of potential U.S. tariffs on Europe tied to President Donald Trump's stance on Greenland, Wall Street attempted a cautious rebound in Wednesday's session. • Lucid Group stock is showing exceptional strength. What’s behind LCID gains?Speaking at the World Economic Forum in Davos, Trump reiterated that acquiring Greenland remains a national security priority for the U.S. He said he expects NATO allies to understand the strategic importance of the issu ...

Every weekday, the CNBC Investing Club with Jim Cramer holds a "Morning Meeting" livestream at 10:20 a.m. ET. Here's a recap of Wednesday 's key moments. 1. Stocks rose Wednesday following President Donald Trump's address at the World Economic Forum, where he eased investor concerns by saying the U.S. wouldn't use force to acquire Greenland. "We had a remarkable resurgence [this morning]," said Jim Cramer, but he added the rally is being led by "the wrong tech," pointing to Micron , which is heavily tied to ...

U.S. stocks traded mixed midway through trading, with the Nasdaq Composite moving lower on Wednesday.The Dow traded up 0.30% to 48,632.75 while the NASDAQ fell 0.06% to 22,940.77. The S&P 500 also rose, gaining, 0.16% to 6,807.83.Leading and Lagging SectorsEnergy shares gained by 2% on Wednesday.In trading on Wednesday, consumer staples stocks dipped by 0.5%.Top HeadlineJohnson & Johnson (NYSE:JNJ) on Wednesday reported better-than-expected fourth-quarter earnings.The company posted adjusted earnings of $2. ...

Full-year 2025 worldwide sales were $94.2 billion, up 5.3% operationally despite an approximate 620 basis point headwind from Stelara. U.S. growth was 6.9% and growth outside the U.S. was 3.4%. Acquisitions and divestitures contributed 110 basis points, driven primarily by the Intra-Cellular and Shockwave acquisitions.For the quarter, net earnings were $5.1 billion and diluted EPS was $2.10 versus $1.41 a year earlier. Adjusted net earnings were $6.0 billion and adjusted diluted EPS was $2.46, representing ...

Key Takeaways J&J posted Q4 EPS of $2.46, beating estimates, as earnings rose 20.6% year over year.JNJ's Innovative Medicines sales climbed 10%, driven by Darzalex, Tremfya and Erleada growth.Oncology drugs like Darzalex and Carvykti delivered strong gains, offsetting Stelara declines.Johnson & Johnson’s (JNJ) fourth-quarter 2025 earnings came in at $2.46 per share, which beat the Zacks Consensus Estimate of $2.43. Earnings rose 20.6% from the year-ago period.Adjusted earnings exclude intangible amortizatio ...

Market Analysis by covering: Johnson & Johnson. Read 's Market Analysis on Investing.com ...